Latest Trials
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
GENENTECH, INC.
🇺🇸
United States
Country
🇺🇸
United States
Ownership
Subsidiary
Established
1976-01-01
Employees
11.1K
Market Cap
-
Website
http://www.gene.com
Clinical Trials
Related News
A Study to Evaluate the Safety and Efficacy of HAE1 in Subjects With Moderate to Severe Allergic Asthma
Phase 2
Completed
Conditions
Allergic Asthma
Subscribe
First Posted Date
2006-12-04
Last Posted Date
2008-01-02
Lead Sponsor
Genentech, Inc.
Target Recruit Count
50
Registration Number
NCT00406965
Subscribe
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Lupus Nephritis Previously Enrolled in Study U2970g
Phase 3
Withdrawn
Conditions
Lupus Nephritis
Subscribe
First Posted Date
2006-11-27
Last Posted Date
2017-04-12
Lead Sponsor
Genentech, Inc.
Registration Number
NCT00404157
Subscribe
A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)
Phase 2
Completed
Conditions
Small Cell Lung Cancer
Interventions
Drug: Chemotherapy
Drug: Bevacizumab
Drug: Placebo
Subscribe
First Posted Date
2006-11-23
Last Posted Date
2011-04-29
Lead Sponsor
Genentech, Inc.
Target Recruit Count
102
Registration Number
NCT00403403
Subscribe
A Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Patients (ALTO)
Phase 3
Completed
Conditions
Asthma
Subscribe
First Posted Date
2006-11-20
Last Posted Date
2014-03-19
Lead Sponsor
Genentech, Inc.
Target Recruit Count
1899
Registration Number
NCT00401596
Subscribe
A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas
Phase 1
Terminated
Conditions
Non-Hodgkin's Lymphoma
Interventions
Drug: Rituximab
Drug: Dulanermin
Subscribe
First Posted Date
2006-11-17
Last Posted Date
2011-11-23
Lead Sponsor
Genentech, Inc.
Target Recruit Count
72
Registration Number
NCT00400764
Subscribe
A Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters
Phase 3
Completed
Conditions
Dysfunctional Central Venous Access Catheters
Interventions
Drug: placebo
Drug: tenecteplase
Subscribe
First Posted Date
2006-11-06
Last Posted Date
2010-08-10
Lead Sponsor
Genentech, Inc.
Target Recruit Count
100
Registration Number
NCT00395876
Subscribe
A Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters
Phase 3
Completed
Conditions
Dysfunctional Central Venous Access Catheters
Interventions
Drug: tenecteplase
Subscribe
First Posted Date
2006-11-06
Last Posted Date
2011-04-27
Lead Sponsor
Genentech, Inc.
Target Recruit Count
251
Registration Number
NCT00396318
Subscribe
A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis Catheters
Phase 3
Completed
Conditions
Dysfunctional Hemodialysis Catheters
Interventions
Drug: placebo
Drug: tenecteplase
Subscribe
First Posted Date
2006-11-06
Last Posted Date
2010-06-03
Lead Sponsor
Genentech, Inc.
Target Recruit Count
150
Registration Number
NCT00396032
Subscribe
A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis (HD) Catheters
Phase 3
Completed
Conditions
Dysfunctional Hemodialysis Catheters
Interventions
Drug: Tenecteplase
Subscribe
First Posted Date
2006-11-06
Last Posted Date
2017-01-12
Lead Sponsor
Genentech, Inc.
Target Recruit Count
223
Registration Number
NCT00396253
Subscribe
A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES)
Completed
Conditions
Colorectal Cancer
Non-Small Cell Lung Cancer
Subscribe
First Posted Date
2006-10-16
Last Posted Date
2022-12-12
Lead Sponsor
Genentech, Inc.
Target Recruit Count
3998
Registration Number
NCT00388206
Subscribe
Prev
1
38
39
40
41
42
49
Next
© Copyright 2024. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy